>
Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc Share Price

$25.86 0.6  2.5%

Last Trade - 16/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £675.7m
Enterprise Value £447.9m
Revenue £n/a
Position in Universe 2891st / 6850
Bullish
Bearish
Unlock BDTX Revenue
Momentum
Relative Strength (%)
1m -6.08%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -44.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BlackDiamond Therapeutics Inc revenues was not reported. Netloss increased 91% to $67.3M. Higher net loss reflectsResearch and development (inclusive of $ increase from$18.6M to $44.6M (expense), General and administrative(inclusive o increase from $7.1M to $17.2M (expense),Stock-based Compensation in R& increase from $472K to $4.2M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BDTX Revenue Unlock BDTX Revenue

Net Income

BDTX Net Income Unlock BDTX Revenue

Normalised EPS

BDTX Normalised EPS Unlock BDTX Revenue

PE Ratio Range

BDTX PE Ratio Range Unlock BDTX Revenue

Dividend Yield Range

BDTX Dividend Yield Range Unlock BDTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BDTX EPS Forecasts Unlock BDTX Revenue
Profile Summary

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. The Company has designed its lead product candidate, BDTX-189, to block the function of an undrugged family of oncogenic proteins defined by mutations which occur across a range of tumor types, and which affect both the epidermal growth factor receptor (EGFR) and the tyrosine-protein kinase ErbB-2, or HER2.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 29, 2014
No. of Shareholders: 39
No. of Employees: 73
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 36,137,635
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BDTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BDTX
Upcoming Events for BDTX
Frequently Asked Questions for Black Diamond Therapeutics Inc
What is the Black Diamond Therapeutics Inc share price?

As of 16/04/21, shares in Black Diamond Therapeutics Inc are trading at $25.86, giving the company a market capitalisation of £675.7m. This share price information is delayed by 15 minutes.

How has the Black Diamond Therapeutics Inc share price performed this year?

Shares in Black Diamond Therapeutics Inc are currently trading at $25.86 and the price has moved by -6.88% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Black Diamond Therapeutics Inc price has moved by -35.81% over the past year.

What are the analyst and broker recommendations for Black Diamond Therapeutics Inc?

There are no analysts currently covering Black Diamond Therapeutics Inc.

When will Black Diamond Therapeutics Inc next release its financial results?

Black Diamond Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Black Diamond Therapeutics Inc dividend yield?

Black Diamond Therapeutics Inc does not currently pay a dividend.

Does Black Diamond Therapeutics Inc pay a dividend?

Black Diamond Therapeutics Inc does not currently pay a dividend.

When does Black Diamond Therapeutics Inc next pay dividends?

Black Diamond Therapeutics Inc does not currently pay a dividend.

How do I buy Black Diamond Therapeutics Inc shares?

To buy shares in Black Diamond Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Black Diamond Therapeutics Inc?

Shares in Black Diamond Therapeutics Inc are currently trading at $25.86, giving the company a market capitalisation of £675.7m.

Where are Black Diamond Therapeutics Inc shares listed? Where are Black Diamond Therapeutics Inc shares listed?

Here are the trading details for Black Diamond Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BDTX
What kind of share is Black Diamond Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Black Diamond Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Black Diamond Therapeutics Inc share price forecast 2021?

Shares in Black Diamond Therapeutics Inc are currently priced at $25.86. At that level they are trading at 0.102% discount to the analyst consensus target price of 0.00.

Analysts covering Black Diamond Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.732 for the next financial year.

How can I tell whether the Black Diamond Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Black Diamond Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -36.94%. At the current price of $25.86, shares in Black Diamond Therapeutics Inc are trading at -13.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Black Diamond Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Black Diamond Therapeutics Inc.

Who are the key directors of Black Diamond Therapeutics Inc?

Black Diamond Therapeutics Inc's management team is headed by:

David Epstein - PRE
Elizabeth Buck - EVP
Alexander Mayweg - DRC
Fang Ni - OTH
Brent Hatzis-Schoch - COO
Thomas Leggett - CFO
Christopher Roberts - CSO
Karsten Witt - SVP
Bradley Bolzon - DRC
Ali Behbahani - IND
Samarth Kulkarni - IND
Rachel Humphrey - OTH
Robert Ingram - CHM
Kapil Dhingra - DRC
Who are the major shareholders of Black Diamond Therapeutics Inc?

Here are the top five shareholders of Black Diamond Therapeutics Inc based on the size of their shareholding:

Versant Ventures Venture Capital
Percentage owned: 17.79% (6.43m shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 9.55% (3.45m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 7.17% (2.59m shares)
Boxer Capital, L.L.C. Hedge Fund
Percentage owned: 5.58% (2.01m shares)
Bellevue Asset Management AG Investment Advisor
Percentage owned: 5.26% (1.90m shares)
Similar to BDTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.